US FDA approves Regeneron's drug for generalized myasthenia gravis

The drug, cemdisiran, branded as Livsayis, was approved for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, the most common form of the disease.



Bengaluru: The US Food and Drug Administration has approved Regeneron Pharmaceuticals' drug to treat adults with a type of rare autoimmune disease called generalized myasthenia gravis, the company said on Wednesday

The drug, cemdisiran, branded as Livsayis, was approved for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, the most common form of the disease.

Generalized myasthenia gravis causes muscle weakness affecting movement, speech, swallowing and breathing.

Livsayis, which is to be injected under the skin once every three months, is the only US-approved treatment for the disease, Regeneron said.

News Source:

https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/us-fda-approves-regenerons-drug-for-generalized-myasthenia-gravis/135974374?utm_source=latest_news&utm_medium=homepage